Clinical observation of patient with obesity and non-alcoholic fatty liver disease case study
- Authors: Komshilova K.A1, Troshina E.A1
-
Affiliations:
- Endocrinology Research Center of the Ministry of Health of the Russian Federation
- Issue: Vol 17, No 4 (2015)
- Pages: 59-61
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94285
- ID: 94285
Cite item
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an obesity-related disease associated especially with abdominal obesity, and various metabolic markers of cardiovascular disease and diabetes mellitus type 2 risk and all these parameters can affect the incidence of disease, prognosis and longevity of people with obesity. The article deals with the case study of observation and treatment of the patient with obesity and NAFLD, associated with a characteristic complex of metabolic disorders. We have shown that combined therapy, including the modification of lifestyle and application of metformin in people with obesity and NAFLD, is safe and effective correction of metabolic disorders.
Full Text
##article.viewOnOriginalSite##About the authors
K. A Komshilova
Endocrinology Research Center of the Ministry of Health of the Russian Federation
Email: komshilovaksenia@rambler.ru
науч. сотр. отд-ния терапии с группой ожирения ФГБУ ЭНЦ 117036, Russian Federation, Moscow, ul. Dmitriia Ul'ianova, d. 11
E. A Troshina
Endocrinology Research Center of the Ministry of Health of the Russian Federationпроф., д-р мед. наук, зав. отд-нием терапии с группой ожирения ФГБУ ЭНЦ 117036, Russian Federation, Moscow, ul. Dmitriia Ul'ianova, d. 11
References
- Targher G et al. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med 2010.
- Misra V.L, Khashab M, Chalasani N. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk. Curr Gastroenterol Rep 2009; 11: 50-5.
- Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocr Rev 2008; 29 (7): 939-60.
- Lazo M, Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28 (4): 339-50.
- Musso G, Gambino R, Cassader M. Non - alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Rev 2010; 11 (6): 430-45.
- Dowman J.K, Tomlinson J.W, Newsome P.N. Pathogenesis of non - alcoholic fatty liver disease. QJM 2010; 103 (2): 71-83.
- Festi D, Colecchia A, Sacco T et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5 (1): 27-42.
- Adams L, Angulo P. Treatment of non - alcoholic fatty liver disease. Postgraduate medical J 2006; 82: 315-22.
- Marchesini G, Bianchi G, Tomassetti S et al. Metformin in non - alcoholic steatohepatitis. Lancet 2001; 358 (9285): 893-4.
- Nair S, Diehl A, Wiseman M. Metformin in the triement of non - alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
- Vernon G, Baranova A, Younossi Z.M. Systematic review: the epidemiology and natural history of non - alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
- Chalasani N, Younossi Z, Lavine J.E et al. The Diagnosis and Management of Non - alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012;107: 811-26.
- Kleiner D.E, Brunt E.M, Van Natta M et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313-21.
Supplementary files
